Monitoring (BIMO) inspections assess sponsor diligence in selecting qualified investigators

EMA CTIS (EU-CTR): Requires inclusion of site and investigator details in Part II of the clinical trial application

PMDA (Japan): Requires a site-specific facility overview in the Clinical Trial Notification (CTN)

CDSCO (India): Expects evidence of EC approval, PI qualification, and site infrastructure details in Form CT-04 or Form CT-06

Documentation of site capabilities is often reviewed during pre-IND meetings, protocol approval reviews, and sponsor inspections. Missing or incomplete documents can result in trial delays or additional queries.

2. Key Documents That Demonstrate Site Capability

Sponsors should compile the following documents for each site under consideration. These should be maintained in the TMF and integrated into regulatory submission packages where required:

Document	Purpose	Where Filed
PI Curriculum Vitae	Demonstrates qualifications and therapeutic experience	Investigator Site File (ISF), TMF
GCP Training Certificate	Confirms compliance with ICH-GCP guidelines	ISF, TMF
Feasibility Questionnaire	Documents site responses on readiness, enrollment potential	Feasibility File, TMF
Site Capability Checklist	Assesses infrastructure, staffing, equipment	Feasibility File, TMF
SOP Index / List	Confirms presence of essential procedures	Site Regulatory Binder, TMF
EC/IRB Approval Letter	Indicates ethics committee authorization	Regulatory Submissions File, TMF
Site Qualification Visit Report	Documents sponsor or CRO assessment findings	Monitoring File, TMF

All documents should be dated, version controlled, signed by appropriate parties, and retained in audit-ready format.

3. Site-Specific Information Required in Regulatory Applications

Depending on the region and regulatory agency, some documents must be included directly in the regulatory submission, not just filed internally.

EU Clinical Trials Information System (CTIS)

Under EU-CTR 536/2014, Part II of the submission includes site information:

• PI name, experience, and qualifications
• Site location, infrastructure, and contact details
• Confirmation of EC approval

All must be entered in the CTIS portal, and inconsistencies during inspection can trigger findings.

FDA IND Submission Expectations

While the FDA does not require every document upfront, they expect sponsors to:

• Document the basis for site selection
• Ensure PI Form FDA 1572 is accurate and signed
• Maintain CVs and training records in TMF
• Provide documents upon request during BIMO inspections

CDSCO and DCGI Submissions (India)

India’s regulations require submission of:

• PI CV, GCP certificate, and site infra details in Form CT-04/CT-06
• EC registration number and approval letter
• Site address and trial responsibilities

Supporting documents must be signed and sealed by the PI or site head.

4. How to Structure and Present Site Capability Documentation

Proper formatting and consistency ensure faster review and better inspection outcomes. Recommendations include:

• Use a standardized Site Readiness Template across all sites
• Group all documents in a dedicated TMF subfolder (e.g., “Site Qualification”)
• Ensure documents are fully signed, dated, and translated (if required)
• Use document headers with site name, protocol ID, and version control
• Maintain consistency between documents and entries in regulatory forms

Example: If a feasibility form indicates 10 years of experience in oncology, but the CV lists only 4 years, this mismatch may result in clarification requests or inspection findings.

5. Best Practices for Sponsors and CROs

• Start collecting site documentation during the feasibility phase
• Maintain a master tracker of site documentation across countries
• Use electronic systems (eTMF, CTMS) to flag incomplete records
• Train feasibility and regulatory teams on regional submission requirements
• Audit a sample of site files quarterly to ensure compliance

6. Real-World Case: EMA Deficiency Linked to Missing Site Documentation

In a Phase III oncology trial submitted via CTIS, the EMA raised a deficiency letter requesting additional documentation for two of the listed sites. Issues identified:

• PI CVs were undated and lacked reference to trial-specific experience
• No EC approval date provided in Part II documentation
• Mismatch in investigator names between Form B and EC letter

The sponsor had to halt site initiation for these centers and submit corrected documents, resulting in a 4-week delay in activation.

7. What to File in the Trial Master File (TMF)

Per the EMA’s TMF Reference Model and FDA guidance, site capability documents should be filed under the following TMF sections:

TMF Section	Documents
4.1 Investigator and Site Qualifications	CVs, GCP training, PI licenses
4.2 Feasibility and Site Selection	Questionnaires, site capability reports
4.3 Regulatory Documentation	EC approvals, IRB communications
4.4 Site Activation	SIV reports, readiness confirmation

Electronic TMFs must maintain metadata, version history, and audit trails for each document.

Conclusion

Documenting site capabilities is not just an internal quality control measure—it is a regulatory obligation that impacts trial startup, compliance, and inspection outcomes. Sponsors and CROs must proactively collect, review, and organize documentation demonstrating that each clinical site meets the operational, ethical, and regulatory standards required for trial participation. By embedding site documentation workflows into feasibility and submission planning, trial teams can ensure smoother regulatory review, faster activations, and greater audit readiness across global trial operations.